← Leaderboards
Kenneth Cundy
Anebulo Pharmaceuticals, Inc.
$1,886,590
Attributed
$1,886,590
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $994.3K · FY2024–25$1M$750K$500K$250K$0
'24
'25
Funding mix
By agency
NIH$1,886,590 · 1
By mechanism
U01$1,886,590 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Acute”
- Taleen Hanania · Psychogenics, Inc.$9,482,040
- Gregory Sorenson · University Of Maryland Baltimore County$9,161,697
- Christopher J. Lindsell · Vanderbilt University Medical Center$8,536,327
- Michael E. Roth · Public Health Institute$8,201,777
- Jacob Sutton Coverstone · Neurovations$6,882,205
- Agustin G Yip · Albert Einstein College Of Medicine$6,090,308
Research focus
AcuteAcute SymptomAdultAdvanced DevelopmentAdverse EventAlertnessAnimal ModelAntagonistAntidotesBody WeightCannabinoid Receptor AntagonistCannabinoidsCannabisChildChildhoodChocolateClinical DevelopmentClinical ResearchCnr1 GeneComaConsensusDeglutitionDesignAccident And Emergency Department
Grant awards (2)
Development of an intravenous CB1 antagonist for acute cannabinoid intoxication and cannabis hyperemesis syndrome$994,300
U01 · FY2025 · DA · contact PI
Development of an intravenous CB1 antagonist for acute cannabinoid intoxication and cannabis hyperemesis syndrome$892,290
U01 · FY2024 · DA · contact PI